Shares of Charles River Laboratories International Inc. (Symbol: CRL) have surpassed the average analyst 12-month target price of $224.75, currently trading at $225.78 per share. This milestone raises questions about potential analyst reactions, which may include downgrading the valuation or raising target prices, depending on business fundamentals.
Analysts have varying target prices for CRL, with the lowest set at $188.70 and the highest at $270.00, indicating a standard deviation of $28.354 among 13 analysts in coverage. Currently, the overall analyst ratings breakdown shows 8 Strong Buy ratings, 5 Hold ratings, and no Sell or Strong Sell ratings, yielding an average rating of 1.77 on a scale where 1 indicates Strong Buy and 5 indicates Strong Sell.
